Pirfenidone improves survival in IPF: results from a real-life study.
BMC Pulm Med
; 18(1): 177, 2018 Nov 23.
Article
en En
| MEDLINE
| ID: mdl-30470213
ABSTRACT
BACKGROUND:
Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone's effect on mortality and adverse events profile outside the restrictions of a clinical trial.METHODS:
This is a retrospective observational intention to treat study of 82 consecutive IPF patients (UHH cohort).RESULTS:
We observed a high 3-years survival rate of 73% without excluding patients who discontinued treatment for different reasons. The survival was compared to the survival of an IPF cohort from a tertiary referral center (RBH cohort). After exclusion of severe cases (DLco< 30%), in unadjusted analysis, the survival in the UHH cohort was better than in the RBH cohort (HR0.32, 95% CI 0.19-0.53, p < 0.0001). After adjustment for age, gender and FVC, the survival remained higher in the UHH cohort (HR0.28, 95% CI 0.16-0.48, p < 0.0001). We observed a similar safety profile compared to previously published data and a lower rate of drug discontinuation due to photosensitivity reactions.CONCLUSION:
Pirfenidone provides a survival benefit in a real-life IPF cohort compared to previously used medications. Counselling patients and proactively managing possible adverse effects can reduce the necessity to discontinue pirfenidone.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piridonas
/
Antiinflamatorios no Esteroideos
/
Fibrosis Pulmonar Idiopática
Tipo de estudio:
Observational_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País como asunto:
Europa
Idioma:
En
Año:
2018
Tipo del documento:
Article